Neuromod Launches Online Tinnitus Masterclass
Neuromod's Tinnitus Masterclass is an expert-led online training program designed to help hearing care professionals deliver clinically effective and commercially sustainable tinnitus services.
Tag: Neuromod
All
Latest
All
Latest
Neuromod Partners with University of South Dakota Clinic to Provide Tinnitus Treatment
Neuromod Devices is expanding access to its Lenire bimodal neuromodulation device, addressing the demand for effective tinnitus treatment.
All
Latest
Lenire Tinnitus Device Now Available in Denmark
Neuromod Devices Ltd has reached an agreement with Specialklinikken Borgå ApS, a Danish provider of private care for tinnitus, to make its Lenire device available in Denmark.
Neuromod Opens USA HQ
Neuromod Devices Ltd, the Irish medical device company specializing in the treatment of tinnitus, has announced the establishment of Neuromod USA Inc, headquartered in Oak Brook, Ill. Three executives with significant experience in the hearing health industry have been appointed to the Neuromod USA leadership team as the organization prepares to enter the US market with its medical device for tinnitus treatment, pending approval from the Food and Drug Administration (FDA).
Read More
Neuromod Appoints Susan Whichard to Board
Whichard has more than 30 years’ experience in the hearing industry, having worked as both a business executive and a practicing healthcare professional, as a clinical audiologist. Her appointment comes as Neuromod plans continued expansion of the availability of Lenire, its tinnitus treatment device across Europe and in the US, pending FDA approval, according to the company’s announcement.
Read More
Survey Shows Many Don’t Receive Tinnitus Treatment
New research from Irish medical device company, Neuromod Devices Ltd, has found that more than three quarters of people suffering from tinnitus in the United Kingdom have never received any treatment for their condition, according to an announcement on the company’s website. The poll also revealed that 67% of UK tinnitus sufferers don’t feel adequately informed about their condition.
Read More
Neuromod Raises $12.4 Million in Series B Funding for Lenire Tinnitus Treatment Device
The investment was led by majority investor Fountain Healthcare Partners, with participation from existing investors Moffett Investment Holdings and Medical Device Resources, with venture-debt provided by Kreos Capital and Silicon Valley Bank.
Read More
Neuromod Publishes Results of Tinnitus Study Utilizing Non-invasive Stimulation Device
The clinical trial was conducted between 2016 and 2019 and was designed to track changes in tinnitus symptom severity. The trial investigated the bimodal neuromodulation approach, using Neuromod’s non-invasive stimulation device that delivers sound to the ears and electrical stimulation to the tongue.
Read More
Neuromod Appoints Rosemarie Tully as COO
In addition to her current responsibilities for corporate development and strategy, Ms Tully will now assume responsibility for all of Neuromod’s operating activities, including manufacturing, supply chain, regulatory, quality, and compliance functions. Ms Tully will continue to report to Dr Ross O’Neill, Chief Executive Officer of Neuromod.
Read More
Neuromod Appoints Florian Elsaesser as Chief Commercial Officer
Elsaesser, a hearing aid industry expert, has worked in the sector for over 12 years in various executive positions for Sivantos and Siemens Audiology.
Read More
American and British Tinnitus Associations Announce Partnership
The American Tinnitus Association (ATA) and British Tinnitus Association (BTA) have announced...
Read More
Neuromod Closes on $8.75 Million Funding Round
Proceeds from the financing will be used to accelerate ongoing European commercialization of the Company’s Lenire tinnitus treatment device; to scale-up manufacturing capacity to meet anticipated European demand, and to progress the Company’s US regulatory strategy to secure market entry into the United States, according to Neuromod’s announcement.
Read More
Neuromod Names New Members of Senior Leadership Team
Neuromod announces the appointment of Deborah Arthur as Head of Quality and Regulatory Affairs, Suzanne O’Rourke as Director of Quality and Regulatory Affairs, and Cathal Mc Fadden as Director of Operations.
Read More
Richard Tyler Appointed to Neuromod’s Clinical Advisory Board
A clinical expert in tinnitus and audiology, Tyler is a pioneer in the advancement of tinnitus research and treatment, founding the annual International Conference on Management of Tinnitus and Hyperacusis more than 26 years ago.
Read More
Neuromod Devices Announces New Appointment to Board of Directors
Neuromod Devices Limited (“Neuromod”), an Irish medical technology company specializing in non-invasive neuromodulation technologies, is pleased to announce that Christopher M. Smith is a Strategic Advisor to the Board as of June 1, 2018 and will join the company’s Board of Directors from January 3, 2019.
Read More
The International Conference on the Management of the Tinnitus and Hyperacusis Patient to Take Place June 14-15, 2018 at The University of Iowa
This conference is intended for otologists, audiologists, psychologists, hearing aid specialists, and nurses who provide clinical management services for patients with tinnitus.
Read More
Neuromod Appoints Dr Hubert Lim as Chief Scientific Officer
Lim’s work has a strong focus on the improvement of invasive and non-invasive neurostimulation approaches for treating unmet medical needs in hearing and other therapeutic areas.
Read More
Multisensory Tinnitus Treatment Receives Certification in Ireland
Neuromod Devices announced that it has secured the CE Mark—certified regulatory approval in Europe—for its mutebutton multisensory tinnitus treatment device.
Read More